Earnings Breakdown: ADMA Biologics Q4
Benzinga Insights 8 months ago
Earnings
The earnings results for ADMA Biologics (NASDAQ:ADMA) for Q4 were made public on Wednesday, February 25, 2026 at 04:05 PM.
Here's a comprehensive overview of the announcement.
Earnings
ADMA Biologics beat estimated earnings by 7.5%, reporting an EPS of $0.215 versus an estimate of $0.2.
Revenue was up $21.61 million from the same period last year.
Previous Earnings Records
The company missed on EPS by $0.0 in the last quarter, resulting in a 8.72% drop share price change the following day.
Here's a look at ADMA Biologics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.16 | 0.14 | 0.14 | 0.15 |
| EPS Actual | 0.16 | 0.14 | 0.14 | 0.14 |
| Revenue Estimate | 130.36M | 121.50M | 116.40M | 112.80M |
| Revenue Actual | 134.22M | 121.98M | 114.80M | 117.55M |
To track all earnings releases for ADMA Biologics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.